When is retreatment of nucleos(t)ide analog (NA) for hepatitis B (HBV) (Hep B) recommended by the WHO?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

Owing to the risk of relapse after discontinuation of NA therapy, the WHO recommends retreatment in the setting of consistent signs of reactivation (positive HBsAg or HBeAg, increasing ALT levels, or redetectable HBV DNA) (where HBV DNA testing is available).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!